FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|September 20, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 20, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of September 15, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 34.7%
• Aged ≥65 years 41.9%
Fully vaccinated plus 1 booster dose:
• Total US population 48.6%
Fully vaccinated in key age groups:
• Total US population 67.7%
• Aged ≥5 years 71.8%
• Aged ≥65 years 92.2%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of September 20, 2022 at 3:23 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 183 352
• Texas 181 773
• Florida 138 717
• Total US confirmed cases 95 761 990
• Total US confirmed deaths 1 054 146
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 612 778 810
• Deaths 6 529 020 • Vaccine doses administered 12 237 803 988
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5